# Gossamer Bio (GOSS) — Analyst Forecast

GOSS · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/goss/forecast

## Analyst consensus

| Consensus | Buy | Hold | Sell | Analysts |
| --- | --- | --- | --- | --- |
| Buy | 4 | 3 | 1 | 8 |

## Recent analyst ratings

| Date | Firm | Action | Rating | Price target |
| --- | --- | --- | --- | --- |
| Oct 15, 2026 | Chardan Capital | Maintained | Buy | $160.00 |
| Oct 13, 2026 | Chardan Capital | Initiated Coverage | Buy | $160.00 |
| Sep 21, 2026 | HC Wainwright & Co. | Maintained | Buy | $90.00 |
| Aug 14, 2026 | Piper Sandler | Maintained | Overweight | $4.00 |
| Jul 28, 2026 | Leerink Partners | Upgraded | Market Perform → Outperform | $1.00 |
| Jul 27, 2026 | HC Wainwright & Co. | Maintained | Buy | $2.00 |
| Jun 25, 2026 | HC Wainwright & Co. | Maintained | Buy | $2.00 |
| May 26, 2026 | HC Wainwright & Co. | Maintained | Buy | $5.00 |
| May 19, 2026 | Barclays | Maintained | Underweight | $0.28 |
| Mar 23, 2026 | Cantor Fitzgerald | Downgraded | Overweight → Neutral | — |
| Mar 6, 2026 | HC Wainwright & Co. | Maintained | Buy | $5.00 |
| Mar 5, 2026 | Oppenheimer | Maintained | Outperform | $3.00 |
| Feb 24, 2026 | Leerink Partners | Downgraded | Outperform → Market Perform | $1.00 |
| Feb 24, 2026 | Barclays | Downgraded | Overweight → Underweight | $0.30 |
| Feb 24, 2026 | Wedbush | Downgraded | Outperform → Neutral | $1.00 |
| Jan 28, 2026 | Barclays | Initiated Coverage | Overweight | $9.00 |
| Jan 22, 2026 | HC Wainwright & Co. | Maintained | Buy | $10.00 |
| Sep 11, 2025 | Cantor Fitzgerald | Maintained | Overweight | — |
| Sep 10, 2025 | UBS | Upgraded | Neutral → Buy | $9.00 |
| Aug 6, 2025 | Wedbush | Maintained | Outperform | $5.00 |

## Frequently Asked Questions

### Is GOSS a buy, sell, or hold?

Analysts covering Gossamer Bio currently average a Buy rating: 4 buy, 3 hold and 1 sell, from 8 analysts. Ratings reflect analyst opinion, not investment advice.

### What is the latest analyst rating on GOSS?

On Oct 15, 2026, Chardan Capital maintained Gossamer Bio at Buy with a price target of $160.00.

---

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).